Navigation Links
Columbia Laboratories' NDA for PROCHIEVE® Vaginal Progesterone Gel Accepted for Filing by FDA
Date:6/27/2011

LIVINGSTON, N.J. and MORRISTOWN, N.J., June 27, 2011 /PRNewswire/ -- Columbia Laboratories, Inc. (Nasdaq: CBRX) and Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing Columbia's New Drug Application (NDA) for PROCHIEVE® (progesterone gel) for the reduction of risk of preterm birth in women with short uterine cervical length in the mid-trimester of pregnancy. The acceptance of the NDA for filing means FDA has determined that the application is sufficiently complete to permit a substantive review. The acceptance for filing does not provide any assurance that the FDA will ultimately approve the NDA.

(Logo: http://photos.prnewswire.com/prnh/20100121/LA41294LOGO)

In addition, Columbia has voluntarily withdrawn its request for priority review. Following discussions with FDA, the companies determined that a standard review would afford the agency the appropriate timeframe necessary to complete its review of the application, including empaneling an agency advisory committee, if necessary.  Under the Prescription Drug User Fee Act III (PDUFA), the FDA's goal under standard review is to review and act on the NDA by February 26, 2012.

Under the terms of the Purchase and Collaboration Agreement between Columbia and Watson, acceptance of the PROCHIEVE NDA will trigger a $5 million milestone payment to Columbia from Watson.

"We are pleased to achieve this important regulatory milestone and look forward to working with the FDA as they review the data package for the PROCHIEVE New Drug Application," said Frank Condella, President and Chief Executive Officer of Columbia Laboratories, Inc.

"Premature birth is a critical problem in this country and currently no therapeutic option exists for preventing preterm birth in women with premature cervical shortening, an emerging risk factor," said Fred Wilkinson, Watson's Executive Vice President, Global Brands.  "The PROCHIEVE New Drug Application represents an important step in the evaluation of a potential new treatment, and if approved, could have a meaningful impact on mothers and the health of their babies, as well as a significant economic impact on the healthcare system."

Columbia submitted the NDA, which includes data from two Phase III clinical trials evaluating the use of PROCHIEVE in reducing the risk of preterm birth in women, as well as supportive pharmacokinetic studies, to the FDA on April 26, 2011.  

About Watson PharmaceuticalsWatson Pharmaceuticals, Inc. is a leading integrated global pharmaceutical company. The Company is engaged in the development and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health. Watson has operations in many of the world's established and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

About Columbia LaboratoriesColumbia Laboratories, Inc. is developing products that utilize its novel bioadhesive drug delivery technologies to optimize drug delivery in a controlled, sustained manner. The Company has developed and sold six products for the U.S. market including CRINONE® (progesterone gel) for which Columbia receives royalties on annual net sales from Watson Pharmaceuticals. CRINONE is commercialized outside the U.S. by Merck Serono.

Columbia's press releases and other company information are available online at http://www.columbialabs.com.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: This communication contains forward-looking statements, which statements are indicated by the words "may," "will," "plans," "intends, " "believes," "expects," "anticipates," "potential," "could," "would," "should," and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those projected in the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. Factors that might cause future results to differ include, but are not limited to, the following: the outcome of further analyses of the clinical data generated during the PREGNANT Study by the FDA; success in obtaining timely approval of PROCHIEVE in the preterm birth indication by the FDA; the impact of competitive products and pricing; the timing and level of success of a future product launch, if any; the ability of Columbia's third-party manufacturers to supply PROCHIEVE; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to manufacturing facilities, products and/or businesses; changes in the laws and regulations, including Medicaid; competitive economic and regulatory factors in the pharmaceutical and healthcare industry; the ability to obtain and enforce patents and other intellectual property rights; general economic conditions; and other risks and uncertainties that may be detailed, from time-to-time, in Columbia's and Watson's reports filed with the SEC, including, but not limited to, their respective Annual Reports on Form 10-K for the year ended December 31, 2010 and Quarterly Report on Form 10-Q for the period ended March 31, 2011. Neither Columbia nor Watson undertake any responsibility to revise or update any forward-looking statements contained herein, except as expressly required by law.

PROCHIEVE® and CRINONE® are registered trademarks of Watson Pharmaceuticals, Inc. For Columbia Laboratories, Inc. For Watson Pharmaceuticals, Inc.Investors  Investors Lawrence A. Gyenes
SVP, Chief Financial Officer & Treasurer
(973) 486-8860Patty Eisenhaur 
VP, Investor Relations and Corp. Comm.
(862) 261-8141--or--Media Seth Lewis
VP, The Trout Group LLC
(646) 378-2952Charlie Mayr
SVP, Corporate Affairs
(862) 261-8030MediaAmy Raskopf

President, Raskopf Communications, LLC

(917) 673-5775
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Columbia University Medical Center and Rosetta Genomics Announce Columbia Universitys Submission of the First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology for Approval to the New York State Department of Health Clinica
2. Terumo Heart, Inc. Reports Clinical Progress in the DuraHeart(TM) U.S. Pivotal Trial as NewYork-Presbyterian Hospital/Columbia University Medical Center Implants First Patient
3. Watson Confirms Columbia Laboratories Filing of Definitive Proxy Relating to Watsons Acquisition of U.S. Rights to CRINONE® Progesterone Gel Product Line
4. Watson Confirms Columbia Laboratories Shareholder Approval of Proposed Acquisition of Progesterone-related Assets
5. Watson Completes Acquisition of CRINONE® and PROCHIEVE® Product Line and Shares of Columbia Laboratories
6. HealthWarehouse.com Partners with Columbia Medical Associates to Bring Affordable Healthcare to Washington State
7. Columbia University Students Learn About Pharmacy Benefit Management From Prime Therapeutics President and CEO
8. Columbia Laboratories to Discuss Fourth Quarter and Year End 2010 Financial Results on March 10, 2011, Conference Call
9. Sanofi-aventis Enters Into Research Collaboration With Columbia University to Develop New Diabetes Treatments
10. Columbia Laboratories and Watson Announce Publication of Positive Phase III PROCHIEVE® Vaginal Progesterone Gel Study Results
11. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... 2017 The top three ... Olympus Corporation, Nikon Corporation, and Leica Microsystems. Collectively ... the overall market in 2015. The oligopolistic market ... result-oriented research and development activities and mergers and ... on expanding their business to emerging economies as ...
(Date:2/22/2017)... and PUNE, India , February 22, 2017 ... was valued at $3,453 million in 2015 and is projected to reach $5,334 million ... implants segment held nearly two-fifths of the total market in 2015. ... ... ...
(Date:2/22/2017)... Feb. 22, 2017  Known for selling everyday ... the widow of prominent California ... know something else about the British conglomerate that makes ... by attempting to steal her late husband,s invention, business ... operated by Dr. Gilbert until his violent death in ...
Breaking Medicine Technology:
(Date:2/22/2017)... ... February 22, 2017 , ... Super-Sod will attend the Athens ... in Athens, Georgia. , A shift from Super-Sod’s simple Athens Home Show booth of ... the booth, grass seed plant manager Chris Roquemore constructed furniture from recycled pallet wood ...
(Date:2/22/2017)... ... , ... Social media marketing is transitioning from a singular person activity to ... delves into this insight and more in its latest episode of its Brains Over ... up with social media strategist and partner of the digital firm Med|Ed Digital Jessica ...
(Date:2/22/2017)... ... February 22, 2017 , ... BrightStar Care Charleston , ... the Medical University of South Carolina (MUSC) Center on Aging’s Senior Expo on ... Center on Aging is a tremendous resource in our community. We are thrilled to ...
(Date:2/22/2017)... ... 2017 , ... In a recent article published ... (age, illness and life choices) should be dissociated from medical errors and preventable ... addition, all too often, studies regarding health system performance in other countries, such ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... chain management (SCM) and spend management, today announced that Keppel Corporation has selected ... simplify expense tracking. , “We are excited to announce the partnership between ...
Breaking Medicine News(10 mins):